Stay updated with breaking news from Equal Life. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
NOVARTIS AG CHF0.50(REGD) Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1 In this st...
Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept
/PRNewswire/ -- Today, Novartis reported the first interpretable year one results of the Phase III MERLIN study, a two-year study initiated in H2 2018,...